Medtronic plc.

Valuation Analysis

About the Company

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and i

Medtronic plc. Stock at a Glance

Medtronic plc. (MDT) is currently trading at $80.20 with a market capitalization of $103B. The trailing P/E ratio stands at 21.5x, with a forward P/E of 12.52x. The 52-week range spans from $73.31 to $106.33; the current price is 24.6% below the yearly high. Year-over-year revenue growth stands at +9.9%. The net profit margin stands at 13.2%.

💰 Dividend

Medtronic plc. pays an annual dividend of $2.88 per share, representing a yield of 3.59%. The payout ratio stands at 76.14%.

📊 Analyst Rating

26 analysts rate Medtronic plc. (MDT) on consensus: Buy. The average price target is $98.00, implying +22.19% from the current price. Analyst price targets range from $78.00 to $121.00.

Medtronic plc.: The Investment Case in Detail

Medtronic plc. (MDT) operates in the Healthcare — specifically Medical Devices — and is headquartered in Ireland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

With a gross margin near 65.38%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Buy with an average price target implying roughly 22.19% upside from current levels — analyst sentiment is firmly constructive.

What to Watch Next

• The forward P/E of 12.52x is meaningfully below the trailing 21.5x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 22.19% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Medtronic plc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.